Management of Prostate Cancer

426 Pages·2013·7.64 MB·English

by  Ranko Miocinovic (auth.), Eric A. Klein, J. Stephen Jones (eds.)

Current Clinical Urology

Eric A. Klein, MD, Series Editor
Chairman, Glickman Urological
and Kidney Institute and Professor of Surgery,
Cleveland Clinic Lerner College of Medicine
Glickman Urological and Kidney Institute
Cleveland, OH
For further volumes:
www.springer.com/series/7635
wwwwwwwwwwww
Eric A. Klein
J. Stephen Jones
Editors
Management of
Prostate Cancer
Third Edition
Editors
Eric A. Klein J. Stephen Jones
Glickman Urological and Kidney Institute Glickman Urological and Kidney Institute
Cleveland Clinic, Cleveland, OH, USA Cleveland Clinic, Cleveland, OH, USA
ISBN 978-1-60761-258-2 ISBN 978-1-60761-259-9 (eBook)
DOI 10.1007/978-1-60761-259-9
Springer New York Heidelberg Dordrecht London
Library of Congress Control Number: 2012943383
© Springer Science+Business Media, LLC 2013
This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part
of the material is concerned, speci fi cally the rights of translation, reprinting, reuse of illustrations,
recitation, broadcasting, reproduction on micro fi lms or in any other physical way, and transmission
or information storage and retrieval, electronic adaptation, computer software, or by similar or
dissimilar methodology now known or hereafter developed. Exempted from this legal reservation
are brief excerpts in connection with reviews or scholarly analysis or material supplied speci fi cally
for the purpose of being entered and executed on a computer system, for exclusive use by the
purchaser of the work. Duplication of this publication or parts thereof is permitted only under the
provisions of the Copyright Law of the Publisher’s location, in its current version, and permission
for use must always be obtained from Springer. Permissions for use may be obtained through
RightsLink at the Copyright Clearance Center. Violations are liable to prosecution under the
respective Copyright Law.
The use of general descriptive names, registered names, trademarks, service marks, etc. in this
publication does not imply, even in the absence of a speci fi c statement, that such names are exempt
from the relevant protective laws and regulations and therefore free for general use.
While the advice and information in this book are believed to be true and accurate at the date of
publication, neither the authors nor the editors nor the publisher can accept any legal responsibility
for any errors or omissions that may be made. The publisher makes no warranty, express or
implied, with respect to the material contained herein.
Printed on acid-free paper
Humana Press is a brand of Springer
Springer is part of Springer Science+Business Media (www.springer.com)
Preface
The information age has not left prostate cancer behind—a search for the
phrase “prostate cancer” in early March 2012 yielded 99,773 citations on
PubMed and an astounding 32, 600, 00 hits on Google! While it only seems
like patients have 32 million internet pages to review in a clinic visit, there is
a staggering amount of new information to be learned, digested, and made
interpretable by physicians for those seeking help. In this volume we have
highlighted the major advances in this fi eld since the Second Edition of
Management of Prostate Cancer appeared in 2004. We have included chap-
ters on the most controversial areas of prostate cancer—screening, chemopre-
vention, and active surveillance and updated chapters on genetic risk and
progression, biopsy schemes, treatment of complications, comparative treat-
ment outcomes for surgery, radiotherapy and brachytherapy, and for locally
advanced disease; and added new chapters on risk factors, new markers,
nomograms, and focal therapy. Perhaps most exciting are overviews of new
and emerging drugs and treatment paradigms for castrate resistant disease,
advances that promise to extend life and perhaps even cure a subset of men
with metastatic disease. These are exciting times for those in the fi eld, and we
hope that this volume will make clinicians’ jobs easier by serving as a con-
densed resource of an expansive universe of information.
Cleveland , OH , USA Eric A. Klein
J. Stephen Jones
v
wwwwwwwwwwww
Contents
1 Epidemiology and Risk Factors ................................................... 1
Ranko Miocinovic
2 Twenty Years and Counting: Is PSA Still
Useful in 2010? .............................................................................. 13
Haluk Ozen and Sertac Yazici
3 Prostate Cancer Screening: A Review
of the Evidence with Clinical Practice Implications .................. 25
Timothy J. Wilt
4 Beyond PSA: Promising New Markers
for Prostate Cancer ....................................................................... 51
Leonard Marks
5 Hereditary Prostate Cancer and Genetic Risk ........................... 79
Adam C. Reese, Graham Casey, and John S. Witte
6 Prostate Inflammation and Prostate Cancer .............................. 103
William G. Nelson, Karen S. Sfanos, Angelo M. DeMarzo,
and Srinivasan Yegnasubramanian
7 Molecular Progression of Prostate Cancer:
Androgens and Estrogens ............................................................. 117
Stephen A. Boorjian and Donald J. Tindall
8 The Role of Obesity and Diet in Prostate Cancer ...................... 127
Jean-Alfred Thomas II and Stephen J. Freedland
9 Prostate Cancer Risk Reduction
by Chemoprevention ..................................................................... 143
Kenneth G. Nepple, Adam S. Kibel, and Gerald L. Andriole
10 Current Issues in Pathologic Evaluation .................................... 153
Sara M. Falzarano, Howard S. Levin, and Cristina Magi-Galluzzi
11 Optimum Prostate Biopsy: Techniques
and Strategies ................................................................................ 177
Osama M. Zaytoun and J. Stephen Jones
vii
viii Contents
12 The Utility of Nomograms in Routine
Clinical Practice ............................................................................ 201
Carvell T. Nguyen and Michael W. Kattan
13 Active Surveillance Comes of Age ............................................... 215
Laurence Klotz
14 Focal Therapy: Prostate Hemiablation
as the First Historical Treatment Model
for Focal Therapy of Early Stage Prostate Cancer .................... 225
Vladimir Mouraviev and Thomas J. Polascik
15 Contemporary External Beam Radiotherapy ............................ 243
Rahul Tendulkar and Kevin Stephans
16 Surgery, Brachytherapy, or External Beam
Radiation for Low- and Intermediate-Risk Disease? ................ 263
Jay P. Ciezki and Eric A. Klein
17 The Role for Radical Prostatectomy in Advanced
Prostate Cancer ............................................................................. 271
R. Jeffrey Karnes and Michael L. Blute
18 Radiation Therapy in the Management of Locally
Advanced Prostate Cancer ........................................................... 281
Joseph D. Mancias and Anthony L. Zietman
19 Clinical Implications of Measuring Quality-of-Life
in Early Stage Prostate Cancer .................................................... 297
Peter Chang, Mehrdad Alemozaffar, and Martin G. Sanda
20 Treatment Modalities of Post-prostatectomy
Incontinence: A Historical Perspective
as Well as Current Therapy Options........................................... 319
Christina Ching and Drogo K. Montague
21 Management of Biochemical Recurrence
After Localized Treatment for Prostate Cancer ......................... 347
Stephen B. Williams and Toni K. Choueiri
22 Management of Newly Diagnosed Metastatic Disease ............... 361
C. Lance Cowey and Thomas E. Hutson
23 Pitfalls of Androgen Deprivation Therapy ................................. 379
Alicia K. Morgans and Matthew R. Smith
24 Current Management of Castration-Resistant
Prostate Cancer (CRPC) .............................................................. 401
Jorge A. Garcia and Robert Dreicer
25 Beta-Emitting Radiopharmaceuticals
and Bone Metastasis ..................................................................... 413
Oliver Sartor
Index ....................................................................................................... 419
Contributors
Mehrdad Alemozaffar , MD Department of Urology , Beth Israel Deaconess
Medical Center, Harvard Program in Urology , Boston , MA , USA
Gerald L. Andriole , MD Division of Urologic Surgery , Washington
University School of Medicine , St. Louis , MO , USA
Michael L. Blute , MD Department of Urology , Mayo Clinic , Rochester , MN ,
USA
Stephen A. Boorjian , MD Department of Urology , Mayo Clinic , Rochester ,
MN , USA
Graham Casey , PhD Department of Preventive Medicine , University of
Southern California Keck School of Medicine , Los Angeles , CA , USA
Peter Chang , MD Department of Urology , Beth Israel Deaconess Medical
Center, Harvard Program in Urology , Boston , MA , USA
Christina Ching , MD Glickman Urological and Kidney Institute , Cleveland
Clinic , Cleveland , OH , USA
Toni K. Choueiri , MD Lank Center for Genitourinary Oncology , D ana-Farber
Cancer Institute and Brigham and Woman’s Hospital , Boston , MA , USA
Jay P. Ciezki , MD Department of Radiation Oncology , Cleveland Clinic ,
Cleveland , OH , USA
C. Lance Cowey , MD Texas Oncology, Charles A. Sammons Cancer Center,
Baylor University Medical Center, Dallas, TX, USA
Angelo M. DeMarzo , MD, PhD Department of Pathology , Johns Hopkins
University School of Medicine , Baltimore , MD , USA
Robert Dreicer , MD, FACP Departments of Solid Tumor Oncology , Taussig
Cancer Institute, Cleveland Clinic , Cleveland , OH , USA
Sara M. Falzarano , MD Pathology and Laboratory Medicine Institute ,
Cleveland Clinic , Cleveland , OH , USA
Stephen J. Freedland , MD Department of Surgery, Division of Urology ,
Duke University Medical Center , Durham , NC , USA
ix